AGP Picks
View all

Nevada Tech Journal
Provided by AGP

Nevada Tech Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nevada Tech Journal.

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

Press releases published on September 28, 2026

Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
30 minutes ago

Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026

Indeterminate GlobeNewswire
New Laudio and AONL Research Links Clinical Ladder Advancement to Higher Nurse Retention, Reveals Early-Career Participation Gap
30 minutes ago

New Laudio and AONL Research Links Clinical Ladder Advancement to Higher Nurse Retention, Reveals Early-Career Participation Gap

Indeterminate GlobeNewswire
Lofty Launches MCP Server to Give Brokerages an Open Foundation for Their AI Strategy
33 minutes ago

Lofty Launches MCP Server to Give Brokerages an Open Foundation for Their AI Strategy

Indeterminate GlobeNewswire
Foresight Plans to Acquire 50.01% in a 270MW Capacity European Data Center Development Company
an hour ago

Foresight Plans to Acquire 50.01% in a 270MW Capacity European Data Center Development Company

Indeterminate GlobeNewswire
Kaltura Wins Best Interactive Content Platform in the 2026 Digiday Technology Awards
an hour ago

Kaltura Wins Best Interactive Content Platform in the 2026 Digiday Technology Awards

Indeterminate GlobeNewswire
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
an hour ago

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Indeterminate GlobeNewswire
ROC Secures $64.3 Million U.S. Department of Justice Contract for Digital Evidence Technology
an hour ago

ROC Secures $64.3 Million U.S. Department of Justice Contract for Digital Evidence Technology

Indeterminate GlobeNewswire
NETSOL Technologies reports record fiscal 2026 revenue and full-year profitability, exceeding guidance
an hour ago

NETSOL Technologies reports record fiscal 2026 revenue and full-year profitability, exceeding guidance

Indeterminate GlobeNewswire
Curonix Announces Published PNS IMPACT Clinical Study Showing Freedom® Peripheral Nerve Stimulator (PNS) System is Associated with Reductions in Pain Scores, Opioid Use and Overall Patient Burden
an hour ago

Curonix Announces Published PNS IMPACT Clinical Study Showing Freedom® Peripheral Nerve Stimulator (PNS) System is Associated with Reductions in Pain Scores, Opioid Use and Overall Patient Burden

Indeterminate GlobeNewswire
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
an hour ago

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Indeterminate GlobeNewswire
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
an hour ago

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

Indeterminate GlobeNewswire
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
an hour ago

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

Indeterminate GlobeNewswire
Core Molding Technologies Promotes Michael J. Gayford to Chief Operating Officer
an hour ago

Core Molding Technologies Promotes Michael J. Gayford to Chief Operating Officer

Indeterminate GlobeNewswire
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
an hour ago

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

Indeterminate GlobeNewswire
icMercury Selected for In-Orbit Validation Mission Aboard PocketQube Satellite on SpaceX Transporter-18
an hour ago

icMercury Selected for In-Orbit Validation Mission Aboard PocketQube Satellite on SpaceX Transporter-18

Indeterminate GlobeNewswire
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
an hour ago

ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)

Indeterminate GlobeNewswire
GOWell Energy Technology Commences Trading on Nasdaq Under Ticker Symbol "GOW”
an hour ago

GOWell Energy Technology Commences Trading on Nasdaq Under Ticker Symbol "GOW”

Indeterminate GlobeNewswire
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
an hour ago

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212

Indeterminate GlobeNewswire
Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer
an hour ago

Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer

Indeterminate GlobeNewswire
Fobi AI (TSXV: FOBI) Issues Corporate Update on Business Transition; Schedules Live Product Demo for October 7
an hour ago

Fobi AI (TSXV: FOBI) Issues Corporate Update on Business Transition; Schedules Live Product Demo for October 7

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Nevada Tech Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.